‘Adimab’s platform, unlike a great many other antibody discovery systems, is free from target restrictions. In addition, Adimab provides its pharma partners with their own unique library diversity that’s not the same as what their competition have. Adimab’s capability to transfer that capability to them has generated considerable interest on the market.’ Related StoriesMorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigensG7 Therapeutics, MorphoSys collaborate on novel antibody therapeutics targeting ion and GPCRs channelsCMC Biologics, River Vision indication manufacturing contract for Teprotumumab to treat Grave's OrbitopathyAdimab and Biogen Idec , of Weston, MA, have initiated a research program whereby Adimab use its proprietary discovery system to identify fully human antibodies against two targets selected by Biogen Idec.Results Follow-up and Randomization Between October 12, 2009, and April 30, 2012, a total of 19,102 individuals underwent randomization; 9550 had been assigned to ivabradine and 9552 to placebo . The last individual check out occurred on January 24, 2014. The median duration of follow-up was 27.8 months . Features of the Participants Both groups were well balanced with respect to baseline characteristics . The mean age of the study people was 65 years, 72.4 percent of the sufferers were men, and the mean resting heartrate was 77.2 beats per minute. A complete of 73.3 percent of the study population had had a prior myocardial infarction, 67.8 percent had had previous coronary revascularization, and 63.